» Articles » PMID: 29866909

Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis Against Enterotoxigenic Escherichia Coli Infection

Abstract

Enterotoxigenic (ETEC) causes diarrheal illness in infants in the developing world and travelers to countries where the disease is endemic, including military personnel. ETEC infection of the host involves colonization of the small intestinal epithelium and toxin secretion, leading to watery diarrhea. There is currently no vaccine licensed to prevent ETEC infection. CFA/I is one of the most common colonization factor antigens (CFAs). The CFA/I adhesin subunit, CfaE, is required for ETEC adhesion to host intestinal cells. Human antibodies against CfaE have the potential to block colonization of ETEC and serve as an immunoprophylactic against ETEC-related diarrhea. Mice transgenic for human immunoglobulin genes were immunized with CfaE to generate a panel of human monoclonal IgG1 antibodies (HuMAbs). The most potent IgG1 antibodies identified in the functional assays were selected and isotype switched to secretory IgA (sIgA) and tested in animal colonization assays via oral administration. Over 300 unique anti-CfaE IgG1 HuMAbs were identified. The lead IgG1 anti-CfaE HuMAbs completely inhibited hemagglutination and blocked adhesion of ETEC to Caco-2 cells. Epitope mapping studies revealed that HuMAbs recognized epitopes in the N-terminal domain of CfaE near the putative receptor binding site. Oral administration of anti-CfaE antibodies in either IgG or sIgA isotypes inhibited intestinal colonization in mice challenged with ETEC. A 2- to 4-log decrease in CFU was observed in comparison to mice challenged with irrelevant isotype controls. We identified fully human monoclonal antibodies against the CfaE adhesion domain that can be potentially employed as an immunoprophylactic to prevent ETEC-related diarrhea.

Citing Articles

Use of an ETEC Proteome Microarray to Evaluate Cross-Reactivity of ETVAX Vaccine-Induced IgG Antibodies in Zambian Children.

Mubanga C, Simuyandi M, Mwape K, Chibesa K, Chisenga C, Chilyabanyama O Vaccines (Basel). 2023; 11(5).

PMID: 37243042 PMC: 10224314. DOI: 10.3390/vaccines11050939.


Daily preventive zinc supplementation increases the antibody response against pathogenic Escherichia coli in children with zinc insufficiency: a randomised controlled trial.

Kewcharoenwong C, Sein M, Nithichanon A, Khongmee A, Wessells K, Hinnouho G Sci Rep. 2022; 12(1):16084.

PMID: 36167891 PMC: 9515173. DOI: 10.1038/s41598-022-20445-8.


Salmonella Uptake into Gut-Associated Lymphoid Tissues: Implications for Targeted Mucosal Vaccine Design and Delivery.

Richards A, Torres-Velez F, Mantis N Methods Mol Biol. 2021; 2410:305-324.

PMID: 34914054 DOI: 10.1007/978-1-0716-1884-4_15.


The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections.

Richards A, Baranova D, Mantis N Hum Vaccin Immunother. 2021; 18(2):1964317.

PMID: 34491878 PMC: 9103515. DOI: 10.1080/21645515.2021.1964317.


Development and Comparison of a Panel of Modified CS17 Fimbrial Tip Adhesin Proteins as Components for an Adhesin-Based Vaccine against Enterotoxigenic .

Liu Y, Maciel Jr M, ODowd A, Poole S, Rollenhagen J, Etobayeva I Microorganisms. 2021; 9(8).

PMID: 34442726 PMC: 8401227. DOI: 10.3390/microorganisms9081646.


References
1.
Luiz W, Rodrigues J, Crabb J, Savarino S, Ferreira L . Maternal vaccination with a fimbrial tip adhesin and passive protection of neonatal mice against lethal human enterotoxigenic Escherichia coli challenge. Infect Immun. 2015; 83(12):4555-64. PMC: 4645407. DOI: 10.1128/IAI.00858-15. View

2.
Qadri F, Svennerholm A, Faruque A, Sack R . Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev. 2005; 18(3):465-83. PMC: 1195967. DOI: 10.1128/CMR.18.3.465-483.2005. View

3.
McArthur M, Maciel Jr M, Pasetti M . Human immune responses against Shigella and enterotoxigenic E. coli: Current advances and the path forward. Vaccine. 2017; 35(49 Pt A):6803-6806. PMC: 5749635. DOI: 10.1016/j.vaccine.2017.05.034. View

4.
Estrada-Garcia T, Cerna J, Paheco-Gil L, Velazquez R, Ochoa T, Torres J . Drug-resistant diarrheogenic Escherichia coli, Mexico. Emerg Infect Dis. 2005; 11(8):1306-8. PMC: 3320511. DOI: 10.3201/eid1108.050192. View

5.
Oh K, Kim D, Jung S, Cho S . Molecular characterization of Enterotoxigenic Escherichia coli strains isolated from diarrheal patients in Korea during 2003-2011. PLoS One. 2014; 9(5):e96896. PMC: 4026316. DOI: 10.1371/journal.pone.0096896. View